PDCD10

Programmed cell death protein 10 · Q9BUL8 · PDCD10 on Sugi Atlas →

0 patent compounds predicted against PDCD10, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PDCD10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) PHASE3COMPLETED
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. PHASE2NOT_YET_RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) PHASE2COMPLETED
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. PHASE2WITHDRAWN
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. PHASE1/PHASE2COMPLETED
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary PHASE2UNKNOWN
MPDL3280A-treatment-IST-UMCG PHASE2UNKNOWN
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma PHASE2COMPLETED
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 PHASE1/PHASE2COMPLETED
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy PHASE2RECRUITING
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer PHASE1/PHASE2UNKNOWN
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma PHASE1COMPLETED
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality nanUNKNOWN
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDCD10 binder may also engage these)

ProteinNameSimilarity
Q8VE70 1.000 Q8VE70 →
Q5ZIV5 1.000 Q5ZIV5 →
Q6DF07 1.000 Q6DF07 →
Q6PHH3 1.000 Q6PHH3 →
Q6NX65 0.999 Q6NX65 →
Q8AVR4 0.998 Q8AVR4 →
Q1ECV8 0.997 Q1ECV8 →
P69267 0.997 P69267 →
Q7KVH9 0.997 Q7KVH9 →
Q67167 0.996 Q67167 →
B2IUK8 0.996 B2IUK8 →
Q06160 0.996 Q06160 →
Q92JM8 0.996 Q92JM8 →
P63309 0.996 P63309 →
P68581 0.996 P68581 →
P07389 0.996 P07389 →
Q57778 0.995 Q57778 →
Q2PIM4 0.995 Q2PIM4 →
P38581 0.995 P38581 →
Q6NWL1 0.995 Q6NWL1 →
P30209 0.995 P30209 →
Q76V07 0.994 Q76V07 →
A8C8W8 0.994 A8C8W8 →
A3DRP5 0.994 A3DRP5 →
P63234 0.994 P63234 →
O95379 0.994 O95379 →
Q67185 0.994 Q67185 →
Q03YQ1 0.993 Q03YQ1 →
Q6P7I6 0.993 Q6P7I6 →
Q5ZT21 0.993 Q5ZT21 →